Breast Cancer Clinical Trial
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well everolimus works in treating women with breast cancer that can be removed by surgery.
Full Description
OBJECTIVES:
Primary
Determine whether the administration of everolimus results in a decrease of total choline, a surrogate marker of response, in at least 30% of women with resectable breast cancer.
Secondary
Determine whether tumors with activated mTOR signaling, as measured by phosphorylation of 4E-BP1 and activity of cap dependent translational complex, will identify those women responsive to everolimus.
OUTLINE: Patients receive oral everolimus once daily on days 1-7 in the absence of disease progression or unacceptable toxicity. Within 24 hours after completing everolimus, patients undergo surgery.
Tumor tissue samples are collected at baseline and during surgery for the analysis of mTOR targets (i.e., 4E-BP1, p70S6 kinase phosphorylation), Ki67, cleaved caspase 3, and activity of cap dependent translational complex by immunohistochemical assays. Patients also undergo MRI/MRS before and after everolimus therapy for total choline and glucose levels measurement.
After completion of study therapy, patients are followed for 30 days.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of invasive breast cancer
Resectable disease
Measurable disease, defined as a primary breast mass > 2.0 cm by breast imaging or clinical exam
Planning to undergo surgical resection after neoadjuvant therapy
Menopausal status not specified
Eastern Clinical Oncology Group (ECOG) performance status 0-1
Absolute neutrophil count (ANC) ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
Hemoglobin > 9.0 g/dL
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 2.5 times upper limit of normal (ULN)
Creatinine ≤ 1.5 times ULN
Total bilirubin ≤ 1.5 times ULN
Not pregnant
Negative pregnancy test
Fertile patients must use effective contraception
Exclusion Criteria:
Intracranial disease
Hormone receptor status not specified
Obese (> 250 pounds)
Immunosuppression from any cause (e.g., known HIV infection)
History of severe asthma and/or allergies
History of severe claustrophobia
Ferromagnetic implants, history of shotgun wound and/or shrapnel, cardiac pacemakers, or other similar situations that would be contrary to strong magnetic force
Bleeding diathesis
Unstable systemic disease, including but not limited to, any of the following:
Uncontrolled diabetes
Severe infection
Severe malnutrition
Uncontrolled hypertension
Unstable angina
Ventricular arrhythmias
Active ischemic heart disease
Congestive heart failure
Myocardial infarction within the past 6 months
Chronic liver disease
Renal disease
Active upper gastrointestinal tract ulceration
Less than 4 weeks since prior investigational drug
Prior therapy with sirolimus or its analogues
Concurrent immunosuppressive therapy (e.g., steroids, cytotoxic agents, or concurrent radiotherapy)
Concurrent anticoagulation (i.e., coumadin)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Minneapolis Minnesota, 55455, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.